Experimental pill promises new hope for deadly pancreatic cancer
CNBC’s Angelica Peebles reports from the American Society of Clinical Oncology, or ASCO, about an experimental pill that promises new hope for pancreatic cancer patients.
The drug is called daraxonrasib, and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
